News
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria -
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS LAUNCHES IPO ON THE SIX SWISS EXCHANGE AND SETS IPO PRICE AT CHF 36.00 PER SHARE
BioVersys launches IPO on the SIX Swiss Exchange with an IPO price set at CHF 36.00 per share. Offering expected to raise approximately CHF 80 million in gross proceeds including over-allotment option -
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS ANNOUNCES INTENTION TO FLOAT ON THE SIX SWISS EXCHANGE
BioVersys AG announces intention to float on SIX Swiss Exchange, targeting primary-only proceeds of approx. CHF 80 million to advance lead asset BV100 through Phase 3 and finance operating expenses. IPO supported by AMR Action Fund and GSK
